PreCyte aims to be the first blood test to score surgical site infection risk within 24 hours of surgery.

Born from our proprietary immune signature technology, PreCyte is designed to give an objective infection-risk score on day one after surgery, helping surgical teams personalize perioperative care for each patient.

PreCyte transforms how we predict and manage surgical risks.

With significantly better predictive performance than existing products and scales, PreCyte Surgical identifies patients at risk for postoperative complications.

By partnering with Surge, clinicians and researchers can monitor the effectiveness of their prevention and treatment protocols throughout the patient pathway to improve outcomes.

Through our PreCyte technology and a standard blood draw, PreCyte Surgical provides real-time information to allow clinicans to tailor their protocols to the biological needs of the individual.

Preoperative

Anticipate surgical risk

PreCyte enables prediction of complications with a simple blood test, identifying patients who would benefit from preoperative interventions such as prehab or optimization of the approach, technique, and timing of surgery. The PreCyte test can be repeated after preoperative interventions (prehab or neoadjuvant treatment), allowing the healthcare team to monitor their effectiveness and continually assess surgical readiness throughout the preoperative period.

Postoperative

Adapt postoperative management

PreCyte combines clinical data from the surgery with the patient's immune response to the surgical trauma the day after surgery to guide patient monitoring, discharge timing, and anticipation and prevention of complications. By accelerating discharge of patients at low-risk for complications, the risk of hospital-acquired infections is decreased and the economic burden of lengthy hospital stays is eased.

Empower improved care
and reduce healthcare costs

By enhancing the patient journey and avoiding complications, PreCyte offers more than outcomes prediction.

63 million elective surgeries are performed annually in the US, with major complication rates reaching 30%. This places a severe burden on patient health and hospital capacity, driving extended stays, avoidable readmissions, and substantial costs.

PreCyte transforms surgical care through individualized risk profiling, empowering surgeons to predict and prevent complications before they occur. Actionable foresight enables surgical risk-adapted lengths of stay and allows care to safely transition toward outpatient settings.
‍
By systematically preventing complications and shortening hospital stays, PreCyte improves patient recovery while capturing billions in potential healthcare savings.

PreCyte is currently under clinical evaluation and is not yet CE marked or FDA cleared.

EVIDENCE AND OPPORTUNITIES FOR CODEVELOPMENT

PreCyte’s clinical performance was assessed in SPRED, a prospective, multicenter, observational cohort study, conducted across five hospitals: Hôpital Foch, Institut Montsouris, Hôpitaux Saint-Joseph, Hôpital Saint-Antoine, and Pitié-Salpêtrière (AP-HP).

283 adults undergoing major elective digestive surgery were enrolled and followed for 30 days. Blood was collected on the first postoperative day and analyzed by cytometry using a seven-marker panel.

The PreCyte-SSI score was built and locked on a training cohort, then tested on a separate validation cohort of patients it had never seen. On that validation set, PreCyte delivered on day one the predictive value that the existing standard, CRP,only reached four days later. SPRED is registered on ClinicalTrials.gov under NCT05523713.

We are now expanding our partnerships in the U.S.